BBB National Programs Decision Summaries
BBB National Programs provides summaries of all case decisions from the National Advertising Division (NAD), National Advertising Review Board (NARB), Children’s Advertising Review Unit (CARU), Direct Selling Self-Regulatory Council (DSSRC), and Digital Advertising Accountability Program (DAAP). Subscribe to receive a weekly wrap-up of published case decisions in your inbox.
- All
-
4/05/2013 - NAD Recommends Matrixx Discontinue Claims that Suggest ‘Zicam’ Products Protect Users from Catching Cold; Found Advertiser Could Support Certain Claims
The National Advertising Division has recommended that Matrixx Initiatives discontinue advertising claims that suggest its homeopathic Zicam Cold Remedy products prevent users from catching a cold. -
4/02/2013 - NAD Finds ASPCA Can Support Advertising Claims Challenged by State Humane Association of California
The National Advertising Division has determined that the American Society for Prevention of Cruelty to Animals (ASPCA) has provided a reasonable basis to support advertising claims made in its fund raising appeals that it provides animal welfare programs and services throughout the United States. NAD has further determined that television and print advertising, challenged by the State Humane Association of California (SHAC), was substantiated and non-misleading. -
3/28/2013 - NAD Recommends Tempur-Pedic Modify, Discontinue Certain Advertising Claims Following Challenge by Serta
The National Advertising Division has recommended that Tempur-Pedic Management, Inc., modify or discontinue certain advertising claims for the company’s premium memory foam mattresses. -
3/28/2013 - NAD Recommends Alde Associates Discontinue Claims that Suggest DaniPro Nail Polish Treats Nail Fungus; Finds Company Can Support ‘Doctor Formulated’ Claim
The National Advertising Division has recommended that Alde Associates discontinue advertising claims for daniPro nail polish, a product infused with the anti-fungal agent undecylenic acid – that state or suggest the product treats or prevents nail fungus. -
3/21/2013 - NAD Recommends Synaptol Discontinue Claims, Testimonials for Synaptol, Promoted as a Treatment for ADD/ADHD
The National Advertising Division has recommended that Hello Life, LLC, discontinue unsupported claims that its Synaptol, a homeopathic remedy, treats or relieves symptoms of Attention Deficit Disorder or Attention Deficit/Hyperactivity Disorder (ADD/ADHD). -
3/20/2013 - NAD Recommends Fuhu Modify, Discontinue Advertising Claims Challenged by LeapFrog Enterprises; Advertiser Agrees to Do So
The National Advertising Division recommended that Fuhu, Inc., the maker of the Nabi2 children’s tablet, modify or discontinue advertising claims challenged before NAD by LeapFrog Enterprises, Inc., maker of the LeapPad, a competing product. The company has agreed to do so. -
3/19/2013 - NAD Examines Claims for Capital One’s Cash Rewards Card Following Chase Challenge
The National Advertising Division determined that Capital One Bank (USA) N.A. took necessary and proper action in discontinuing certain television commercials for its Cash Rewards credit card. NAD determined that a separate set of broadcast ads and a related direct mail advertisement were not misleading. -
3/19/2013 - NAD Finds L’Oreal Acted Properly in Discontinuing Mascara Advertising that Incorporated Post-Production ‘Enhancement’ Disclosure
The National Advertising Division determined that L’Oreal USA acted properly in working toward the discontinuance of certain in-store advertising. -
3/11/2013 - National Advertising Review Board Welcomes 21 New Members From Nation’s Top Companies, Ad Agencies, Universities
The National Advertising Review Board (NARB) has named 21 new members to the advertising industry’s only peer-review process – a body that serves to assure that advertising claims are truthful and accurate. NARB members are selected for their standing in the industry. Their volunteer service to NARB is an invaluable component of advertising industry self-regulation. -
3/05/2013 - NAD Refers Advertising for Star Herbs’ ‘My Low Press’ to FTC for Further Review
The National Advertising Division has referred advertising for “My Low Press,” a dietary supplement marketed by Star Herbs, LLC, to the Federal Trade Commission for further review, after the company declined to participate in a NAD review of its advertising claims.